Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Bosakitug (ATI-045) in Atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
6/2/25- Initiated Ph2 trial with topline data in H2 2026. 11/06/25:- Enrollment ongoing in Ph2 AD trial; topline results reiterated for H2 2026. 02/26/26:- Bosakitug randomized Phase 2 AD trial ongoing; topline results reiterated for H2 2026. 03/18/26:- Completed enrollment in Ph2 AD trial; topline results expected Q4 2026. 05/07/26:- Confirmed completed Ph2 AD enrollment and reiterated Q4 2026 topline results expectation. 08/06/26:- Bosakitug AD Ph2 topline results remain on track for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.